Health Affairs May 24, 2023
Karim Sariahmed, Marc LaRochelle, Benjamin P. Linas

Throughout the COVID-19 pandemic, the US has put its faith and the greatest amount of resources into biomedical technology, with the use of non-pharmaceutical interventions (such as masking or behavior change) increasingly left to individuals. Multiple monoclonal antibodies or “biologics” for COVID-19 have had their Food and Drug Administration (FDA) authorizations withdrawn, but this has received relatively little public attention, despite the implications for the state of our drug pipeline and for public health more broadly. In response to a variety of drug development challenges during the pandemic, many have correctly called for revamping our clinical trial infrastructure, but this particularly remarkable series of disappointments should prompt a variety of other policies to reduce upstream profiteering and better integrate drug...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Pharma / Biotech, Public Health / COVID
What New Gene Therapy Means For Sickle Cell Patients
Inside this year’s ASCO: Biggest data drops, trends and the best exhibit booth
2024 Pharm Exec Top 50 Companies
Federal Support Should Not Be A Factor In Determining Pharmaceutical Prices Under The IRA
Chutes & Ladders—Longtime J&J exec retiring after 17 years

Share This Article